Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

NCT06625970 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

700

Enrollment

OTHER

Sponsor class

Conditions

High Risk Prostate Carcinoma
Prostate Cancer

Interventions

DRUG: Darolutamide
RADIATION: Stereotactic Body RadioTherapy (SBRT)
DRUG: ADT (Standard of Care)
RADIATION: radiotherapy

Sponsor

UNICANCER

Collaborators

[object Object]